Clinical trial
Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain.
NCT00290901 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00290901 |
|---|---|
| Title | Celebrex vs Tramadol in the Treatment of Chronic Lower Back Pain. |
| Official title | A Six Week Double-Blind, Randomized, Multicenter Comparison Study of the Analgesic Effectiveness of Celecoxib 200 mg BID Compared to Tramadol Hydrochloride 50 mg QID in Subjects With Chronic Low Back Pain |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Back Pain |
| Intervention type | Drug |
| Interventions | Tramadol Hydrochloride 50mg, Celebrex 200mg |
| Enrollment | 754 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2006 |
| First posted | Feb 13, 2006 |
| Last update posted | Mar 3, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: